. Author manuscript; available in PMC: 2023 Sep 1.

Published in final edited form as: Pancreatology. 2022 May 31;22(6):760–769. doi: 10.1016/j.pan.2022.05.003

Table 2:

Genetic mutation assumptions

Germline Genetic Mutation	Prevalence among PDAC Patients	Relative Risk of PDAC (Range)	Source
ATM	1.0 %	2.4 (2.41 – 5.71)	73, 74
BRCA1	0.7 %	1.6 (1.0 – 2.8)	3, 15, 16, 63, 68, 73, 79
BRCA2	2.4 %	3.2 (2.13 – 6.8)	3, 17, 63, 68, 73, 79
CDKN2A	2.0 %	12.7 (12.3 – 47.8)	21–25, 66, 73
Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)	1.5 %	5.9 (5 – 10.7)	14, 73, 80
PALB2	1.0 %	3.2 (2.37 – 4)	81
STK11	0.01 %	24 (up to 132)	19
TP53	0.4 %	6.3 (3 – 7.3)	69, 73
Overall	9.0 %		3, 4, 11, 12, 14–25, 60–74. 79–81